<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        21-5287-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OXALIPLATIN HOSPIRA 5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXALIPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        619.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Zydus Hospira Oncology Private Limited ZHOPL " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Zydus Hospira Oncology Private Limited ZHOPL 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA UK LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient of Oxaliplatin Hospira is oxaliplatin.</p><p>&nbsp;</p><p>Oxaliplatin is used to treat cancer of the large bowel (treatment of stage III colon cancer after complete resection of primary tumour, metastatic cancer of colon and rectum). Oxaliplatin is used in combination with other anticancer medicines called 5-fluorouracil and folinic acid.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxaliplatin is an antineoplastic or anticancer drug and contains platinum.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Oxaliplatin Hospira if:</strong></p><ul><li>You are allergic to oxaliplatin, or any of the other ingredients of this medicine (listed in section 6)</li><li>You are breast-feeding,</li><li>You already have a reduced number of blood cells,</li><li>You already have tingling and numbness in the fingers and/or toes, and have difficulty performing delicate tasks, such as buttoning clothes,</li><li>You have severe kidney problems.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before taking Oxaliplatin Hospira:</p><ul><li>If you have ever suffered an allergic reaction to platinum-containing medicines such as carboplatin, cisplatin. Allergic reactions can occur during oxaliplatin infusion,</li><li>If you have moderate or mild kidney problems,</li><li>If you have any liver problems or abnormal liver function results during your treatment,</li><li>If you have or had heart disorders such as an abnormal electrical signal called prolongation of the QT interval, an irregular heart beat, or a family history of heart problems.</li><li>If you have recently received or plan to receive any vaccines. During treatment with oxaliplatin, you should not have a vaccination with &ldquo;live&rdquo; or &ldquo;attenuated&rdquo; vaccines, such as yellow fever vaccine.</li></ul><p>&nbsp;</p><p><strong>Other medicines and Oxaliplatin Hospira</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including vaccines.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>&nbsp;</p><p><u>Pregnancy</u><strong><u> </u></strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;It is not recommended that you become pregnant during treatment with oxaliplatin and must use an effective method of contraception. Female patients should take appropriate contraceptive measures during and after cessation of therapy continuing for 4 months.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are pregnant or planning a pregnancy it is very important that you discuss this with your doctor <strong>before </strong>you receive any treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you get pregnant during your treatment, you must immediately inform your doctor.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>You must not breast-feed while you are treated with oxaliplatin.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Oxaliplatin may have an anti-fertility effect, which could be irreversible. Male patients should seek advice on conservation of sperm prior to treatment.</p><p>&nbsp;</p><p>Male patients are advised not to father a child during treatment and until 6 months after treatment and to take appropriate contraceptive measures during this time.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Oxaliplatin treatment may result in an increased risk of dizziness, nausea and vomiting, and other neurological symptoms that affect walking and balance. &nbsp;</p><p>&nbsp;</p><p>If this happens you should not drive or operate machinery. If you have vision problems while taking oxaliplatin, do not drive, use heavy machines or engage in dangerous activities.</p><p><strong>&nbsp;</strong></p><p><strong>Oxaliplatin Hospira contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>For adults only. </strong></p><p>&nbsp;</p><p>Oxaliplatin is intended only for adults.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The dose of oxaliplatin is based on your body surface area. This is calculated from your height and weight. The usual dose for adults, including the elderly is 85 mg/m<sup>2</sup> of body surface area. The dose you receive will also depend on results of blood tests and whether you have previously experienced side effects with oxaliplatin.</p><p>&nbsp;</p><p><strong>Method and route of administration</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxaliplatin will be prescribed for you by a specialist in cancer treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be treated by a healthcare professional, who will have made up the required dose of oxaliplatin.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxaliplatin is given by slow injection into one of your veins (an intravenous infusion) over a 2 to 6 hour period.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxaliplatin will be given to you at the same time as folinic acid and before the infusion of 5-fluorouracil.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Frequency of administration</strong></p><p>You should usually receive your infusion once every 2 weeks.</p><p>&nbsp;</p><p><strong>Duration of treatment</strong></p><p>The duration of treatment will be determined by your doctor. &nbsp;Your treatment will last a maximum of 6 months when used after complete resection of your tumour</p><p>&nbsp;</p><p><strong>If you are given more Oxaliplatin Hospira than you should:</strong></p><p>&nbsp;</p><p>As this medicine is administered by a healthcare professional, it is highly unlikely that you will be given too much or too little. &nbsp;</p><p>&nbsp;</p><p>In case of overdose, you may experience increased side effects. Your doctor may give you appropriate treatment for these side effects.</p><p>&nbsp;</p><p>If you have any questions about your treatment, ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any side effect it is important that you inform your doctor before your next treatment.</p><p>You will find described below the side effects that you could experience.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately if you notice any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptoms of an allergic or anaphylactic reaction with sudden signs such as rash, itching or hives on the skin, difficulties in swallowing, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing, extreme tiredness (you may feel you are going to faint). In the majority of cases, these symptoms occurred during the infusion or immediately after but delayed allergic reactions have also been observed hours or even days after the infusion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal bruising, bleeding or signs of infection such as a sore throat and high temperature,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Persistent or severe diarrhoea or vomiting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of blood or dark brown coffee-coloured particles in your vomit,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you faint (lose consciousness) or have an irregular heartbeat while taking Oxaliplatin Hospira, tell your doctor immediately as this may be a sign of a serious heart condition,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience muscle pain and swelling, in combination with weakness, fever, or red brown urine, tell your doctor. These could be signs of muscle damage (rhabdomyolysis) and could lead to kidney problems or other complications,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomatitis/mucositis (sore lips or mouth ulcers),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory symptoms such as dry or wet cough, difficulties in breathing or crackles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath and, wheezing as these may be indications of a serious lung disease that may lead to death,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A group of symptoms such as headache, altered mental functioning, seizures and abnormal vision from blurriness to vision loss (symptoms of reversible posterior leukoencephalopathy syndrome, a rare neurological disorder),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke symptoms (including sudden severe headache, confusion, trouble seeing in one or both eyes, numbness or weakness of face, arm or leg usually on one side, face dropping, trouble walking, dizziness loss of balance and speech difficulty),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme tiredness with decreased number of red blood cells, and shortness of breath (haemolytic anaemia), alone or combined with low platelet count, abnormal bruising (thrombocytopenia) and kidney disease where you pass little or no urine (symptoms of Haemolytic-uraemic syndrome).</p><p><strong>&nbsp;</strong></p><p><strong>Other known side effects of oxaliplatin are:</strong></p><p>&nbsp;</p><p><strong><u>Very common (may affect more than 1 in 10 people): </u></strong></p><p><strong>&nbsp;</strong></p><p>Oxaliplatin can affect the nerves (peripheral neuropathy). You may feel a tingling and/or numbness in the fingers, toes, around the mouth or in the throat, which may sometimes occur in association with cramps.</p><p>&nbsp;</p><p>These effects are often triggered by exposure to cold e.g. opening a refrigerator or holding a cold drink. You may also have difficulty in performing delicate tasks, such as buttoning clothes. Although in the majority of cases these symptoms resolve themselves completely, there is a possibility of persistent symptoms of peripheral sensory neuropathy after the end of the treatment.</p><p>&nbsp;</p><p>Some people have experienced a tingling, shock-like sensation passing down the arms or trunk when the neck is flexed.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Oxaliplatin can sometimes cause an unpleasant sensation in the throat, in particular when swallowing, and give the sensation of shortness of breath. This sensation, if it happens, usually occurs during or within hours of the infusion and may be triggered by exposure to the cold.</p><p>&nbsp;</p><p>Although unpleasant, it will not last long and goes away without the need for any treatment. Your doctor may decide to alter your treatment as a result.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Oxaliplatin may cause diarrhoea, mild nausea (feeling sick) and vomiting (being sick); however medication to prevent the sickness is usually given to you by your doctor before treatment and may be continued after treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Oxaliplatin causes temporary reduction in the number of blood cells. The reduction of red cells may cause anaemia (a reduction of red cells), abnormal bleeding or bruising (due to a reduction in platelets).</p><p>&nbsp;</p><p>The reduction in white blood cells may make you prone to infections.</p><p>&nbsp;</p><p>Your doctor will take blood to check that you have sufficient blood cells before you start treatment and before each subsequent course.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Sensation of discomfort close to or at the injection site during the infusion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Fever, rigors (tremors), mild or severe tiredness, body pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Weight changes, loss or lack of appetite, taste disorders, constipation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Headache, back pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Swelling of the nerves to your muscles, neck stiffness, abnormal tongue sensation possibly altering speech, stomatitis/mucositis (sore lips or mouth ulcers),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Stomach pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Abnormal bleeding including nose bleeds,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Coughing, difficulty in breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Allergic reactions, skin rash which may be red and itchy, mild hair loss (alopecia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Alteration in blood tests including those relating to abnormalities in liver function.</p><p><strong>&nbsp;</strong></p><p><strong><u>Common (may affect up to 1 in 10 people):</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Infection due to a reduction in white blood cells,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Serious infection of the blood in addition to a reduction in white blood cells (neutropenic sepsis), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Reduction in white blood cells accompanied by fever &gt; 38.3&deg;C or a prolonged fever &gt; 38&deg;C for more than one hour (febrile neutropenia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Indigestion and heartburn, hiccups, flushing, dizziness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Increased sweating and nail disorders, flaking skin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Chest pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Lung disorders and runny nose,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Joint pain and bone pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Pain on passing urine and changes in kidney function, changes of frequency of urination, dehydration,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Blood in the urine/stools, swelling of the veins, clots in the lung,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;High blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Depression and insomnia,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Conjunctivitis and visual problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Decreased levels of calcium in the blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Fall.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong><u>Uncommon (may affect up to 1 in 100 people):</u></strong><strong> </strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp; &nbsp;Serious infection of the blood (sepsis), which may be fatal,</p><p>&bull;&nbsp; Blockage or swelling of the bowel,</p><p>&bull;&nbsp; Nervousness.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong><u>Rare (may affect up to 1 in 1,000 people):</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Loss of hearing,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Scarring and thickening in the lungs with difficulties in breathing, sometimes fatal (interstitial lung disease),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Reversible short-term loss of vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Unexpected bleeding or bruising due to widespread blood clots throughout the small blood vessels of the body (disseminated intravascular coagulation), which may be fatal.</p><p><strong><u>&nbsp;</u></strong></p><p>&nbsp;</p><p><strong><u>Very rare (may affect up to 1 in 10 000 people)</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of blood or dark brown coffee-coloured particles in your vomit,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disease where you pass little or no urine (symptoms of acute renal failure).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular disorders of liver.</p><p>&nbsp;</p><p><strong><u>Not known (frequency cannot be estimated from available data)</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic vasculitis (inflammation of blood vessels),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Auto-immune reaction leading to reduction of all blood cell lines (autoimmune pancytopenia) pancytopenia,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious infection of the blood and low blood pressure (septic shock), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (uncontrolled shaking of the body),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spasm of the throat causing difficulty in breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme tiredness with decreased number of red blood cells, and shortness of breath (haemolytic anaemia), alone or combined with low platelet count and kidney disease where you pass little or no urine (symptoms of Haemolytic‑uraemic syndrome), which may be fatal, have been reported,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal heart rhythm (QT prolongation), that can be seen on electrocardiogram (ECG), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack (myocardial infarction), pain or uncomfortable feeling in the chest (angina pectoris),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lining of the oesophagus &ndash; the tube that connects your mouth with your stomach &ndash; resulting in pain and swallowing difficulty (oesophageal inflammation),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain and swelling, in combination with weakness, fever, or red-brown urine (symptoms of muscle damage called rhabdomyolysis), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, nausea, bloody vomit or vomit that looks like &quot;coffee grounds&quot;, or dark coloured/tarry stools (symptoms of gastrointestinal ulcer, with potential bleeding or perforation), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood flow to the intestine/bowel (intestinal ischaemia), which may be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk of new cancers. Leukaemia, a form of blood cancer, has been reported in patients after taking Oxaliplatin in combination with certain other medicines. Talk to your doctor about the potential for increased risk of this type of cancer when taking Oxaliplatin and certain other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cancerous abnormal liver nodules (focal nodular hyperplasia).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><ul><li>Call center: 19999</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority </em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children. Keep the vial in the outer carton in order to protect from light. Do not freeze.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Once diluted the infusion preparation should be used immediately. &nbsp;Chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C and 6 hours at 25&deg;C. &nbsp;If not used immediately, in-use storage times and conditions are the responsibility of the user and would not normally be longer than 24 hours at 2&deg;C to 8&deg;C.</p><p>Oxaliplatin should not come into contact with the eyes or skin. If there is any accidental spillage, tell the doctor or nurse immediately.</p><p>&nbsp;</p><p>When the infusion has finished, oxaliplatin will be disposed of carefully by the doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is oxaliplatin.</p><p>One ml of concentrate for solution for infusion contains 5 mg oxaliplatin. &nbsp;</p><p>10 ml of concentrate for solution for infusion contains 50 mg of oxaliplatin.</p><p>20 ml of concentrate for solution for infusion contains 100 mg of oxaliplatin.</p><p>40 ml of concentrate for solution for infusion contains 200 mg of oxaliplatin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are tartaric acid, sodium hydroxide and water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oxaliplatin Hospira is in the form of a concentrate solution for infusion (a concentrated solution which is diluted to make a solution which can be given as a slow infusion via a drip). Each millilitre (ml) of solution contains 5 milligrams (mg) of oxaliplatin. It is a clear, colourless solution contained in glass containers called vials, containing 50 mg (10 ml), 100 mg (20 ml) and 200 mg (40 ml) of oxaliplatin. The vials are wrapped in a protective plastic to reduce the risk of spillage if the vials break - these are referred to as ONCO-TAIN®. The vials are available in single packs.

The solution is then diluted in glucose 5% solution and can be given as an infusion via a drip.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>Hospira UK Limited</p><p>Horizon</p><p>Honey Lane</p><p>Hurley</p><p>Maidenhead</p><p>SL6 6RJ</p><p>UK</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><ul><li>Zydus Hospira Oncology Private Limited, Plot No.3, Pharmez - Special Economic Zone, Sarkhej Bavla Highway, (N.H, No. 8A), Matoda, Taluka Sanand, District Ahmedabad &ndash; 382213,, Ahmedabad, India</li></ul><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	December 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المكون الفعال في أوكساليبلاتن هوسبيرا هو أوكساليبلاتن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم أوكساليبلاتن لعلاج سرطان الأمعاء الغليظة (علاج سرطان القولون من المرحلة الثالثة بعد الاستئصال الكامل للورم الأساسي، وسرطان القولون والمستقيم المنتشر). يستخدم أوكساليبلاتن بالتزامن مع أدوية أخرى مضادة للسرطان تسمى ٥-فلورويوراسيل وحمض الفولينيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أوكساليبلاتن هو عقار مضاد للأورام أو مضاد للسرطان يحتوي على البلاتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أوكساليبلاتن هوسبيرا:</strong></p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه أوكساليبلاتن، أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين رضاعة طبيعية،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني بالفعل من انخفاض عدد خلايا الدم،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالفعل بالخدر والتنميل في أصابع يديك و/أو قدميك، وتواجه صعوبة في أداء المهام الدقيقة مثل تزرير الملابس،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة بالكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال أوكساليبلاتن هوسبيرا</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول أوكساليبلاتن هوسبيرا:</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد سبق أن عانيت من تفاعل حساسية تجاه أدوية تحتوي على البلاتين مثل كاربوبلاتين، سيسبلاتين. قد تحدث تفاعلات الحساسية خلال تسريب أوكساليبلاتن،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات خفيفة أو متوسطة بالكلى،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشكلات في الكبد أو كانت نتائج اختبارات وظائف الكبد غير طبيعية أثناء علاجك،</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو سبق أن عانيت من اضطرابات في القلب مثل إشارات كهربائية غير طبيعية لقلبك تسمى إطالة فترة QT أو عدم انتظام نبضات القلب أو تاريخ عائلي من الإصابة بمشكلات بالقلب.</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت مؤخرًا أو كنت تخطط لتلقي أي لقاحات. أثناء العلاج بأوكساليبلاتن، ينبغي ألا تتلقى لقاحًا &quot;حيًا&quot; أو &quot;موهنًا&quot;، مثل لقاح الحمى الصفراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية </strong><strong>من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتلقى أو تلقيت مؤخرًا أو قد تتلقى أي أدوية أخرى، بما في ذلك اللقاحات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل<strong> </strong></u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى بأن تصبحي حاملًا أثناء العلاج بأوكساليبلاتن ويجب استخدام وسيلة فعالة لمنع الحمل. ينبغي للمريضات استخدام وسائل منع الحمل المناسبة أثناء العلاج وبعد إيقافه لمدة ٤ أشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تخططين لتصبحي حاملًا، فمن المهم للغاية أن تناقشي هذا مع طبيبكِ <strong>قبل </strong>تلقيكِ لأي علاج.</p><p dir="RTL">&bull; إذا أصبحتِ حاملًا أثناء علاجكِ، يجب عليكِ إخبار طبيبكِ على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرضاعة الطبيعية</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ عدم القيام بالرضاعة الطبيعية أثناء علاجكِ بأوكساليبلاتن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون لأوكساليبلاتن تأثير مضاد للخصوبة، ويمكن أن يكون هذا التأثير غير قابل للعكس. ينبغي على المرضى من الرجال طلب المشورة فيما يتعلق بحفظ الحيوانات المنوية قبل العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينصح المرضى من الرجال بعدم إنجاب طفل أثناء العلاج وحتى ٦ أشهر بعد العلاج واستخدام وسائل منع الحمل المناسبة خلال ذلك الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تلقي أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير أوكساليبلاتن هوسبيرا على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي العلاج بأوكساليبلاتن إلى زيادة خطر التعرض للدوار والغثيان والقيء وأعراض عصبية أخرى تؤثر على المشي والتوازن.&nbsp; إذا حدث ذلك، ينبغي ألا تقوم بالقيادة أو تشغيل الآلات. إذا أصبت بمشكلات في الرؤية أثناء تلقي أوكساليبلاتن، فلا تقم بالقيادة أو تشغيل الآلات الثقيلة أو المشاركة في الأنشطة الخطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أوكساليبلاتن هوسبيرا<strong> يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول (٢٣ ملجم) من الصوديوم في كل قارورة، أي أنه &quot;خالٍ من الصوديوم&quot; تقريبًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>للبالغين فقط. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أوكساليبلاتن مخصص للبالغين فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">يتم تحديد جرعة أوكساليبلاتن وفقًا لمساحة سطح الجسم. ويتم حسابها من خلال طولك ووزنك. الجرعة المعتادة للبالغين، بما في ذلك المسنين هي ٨٥ ملجم/م<sup>٢</sup> من مساحة سطح جسمك. تعتمد الجرعة التي ستتلقاها أيضًا على نتائج فحوصات الدم وإذا ما كنت قد تعرضت لآثار جانبية في السابق نتيجة استخدام أوكساليبلاتن أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال ومسار التعاطي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; سيتم وصف أوكساليبلاتن لك من قبل أخصائي في علاج السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; سيعالجك أخصائي رعاية صحية، وهو الذي سيحدد الجرعة اللازمة من أوكساليبلاتن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; يتم إعطاء أوكساليبلاتن عن طريق الحقن البطيء في أحد أوردتك (تسريب عبر الوريد) على مدار ساعتين إلى ٦ ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; سيتم إعطاؤك أوكساليبلاتن في نفس الوقت مع حمض الفولينيك وقبل تسريب ٥-فلورويوراسيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معدل الاستعمال</strong></p><p dir="RTL">ينبغي عليك عادةً تلقي التسريب &nbsp;الوريدى مرة واحدة كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">سيحدد طبيبك مدة العلاج.&nbsp; سيستمر علاجك لفترة أقصاها ٦ أشهر عند استخدامه بعد الاستئصال الكامل للورم لديك</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ- الجرعة الزائدة من أوكساليبلاتن هوسبيرا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأن هذا الدواء يتم إعطاؤه بواسطة أخصائي رعاية صحية، فإنه من المستبعد بشكل كبير أن يتم إعطاؤك أكثر أو أقل مما ينبغي.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة تلقي جرعة مفرطة، فإنك قد تتعرض إلى زيادة شدة الأثار الجانبية. قد يقوم طبيبك بإعطائك العلاج المناسب لهذه الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة بشأن علاجك، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.&nbsp; إذا تعرضت لأي آثار جانبية، فمن المهم أن تخبر طبيبك قبل تلقيك لعلاجك التالي.</p><p dir="RTL">ستجد الآثار الجانبية التي قد تتعرض لها موضحة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا لاحظت ظهور أي مما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض لتفاعلات حساسية أو تفاعلات تأقية مصحوبة بعلامات مفاجئة مثل الطفح الجلدي أو الحكة أو ظهور الشرى على الجلد، صعوبات في البلع، تورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم، ضيق التنفس، الأزيز أو صعوبة التنفس، التعب الشديد (قد تشعر بأنك على وشك الإصابة بالإغماء). في أغلب الحالات، تحدث هذه الأعراض خلال التسريب أو بعده مباشرة، ولكن قد تمت ملاحظة حدوث تفاعلات حساسية متأخرة أيضًا بعد ساعات أو حتى أيام من التسريب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدم غير طبيعي أو نزيف أو علامات الإصابة بعدوى مثل احتقان الحلق وارتفاع درجة الحرارة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو قيء مستمر أو شديد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود جسيمات دموية أو بنية داكنة بلون القهوة في قيئك،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بإغماء (فقدت الوعي) أو كانت ضربات القلب لديك غير منتظمة أثناء تناول أوكساليبلاتن هوسبيرا، فأخبر طبيبك على الفور لأنها قد تكون علامة على الإصابة بحالة قلبية خطيرة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم العضلات وتورمها، مصحوبًا بضعف، أو حمى، أو بول لونه أحمر يميل إلى البني، فأخبر طبيبك. قد تكون هذه علامات لتلف العضلات (انحلال الربيديات) ويمكن أن تؤدي إلى مشكلات في الكلى أو مضاعفات أخرى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم/الغشاء المخاطي (تقرح الشفتين أو قرح الفم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تنفسية مثل السعال الجاف أو الرطب، أو صعوبات في التنفس، أو القرقعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس والأزيز حيث قد تكون هذه مؤشرات على الإصابة بمرض رئوي خطير يمكن أن يؤدي إلى الوفاة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة من الأعراض مثل الصداع، وتغير الوظائف العقلية، والنوبات، ورؤية غير طبيعية تتراوح من ضبابية الرؤية إلى فقدان الرؤية (أعراض اعتلال المادة البيضاء في الفص الخلفي من الدماغ القابل للعكس، وهو اضطراب عصبي نادر)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض السكتة الدماغية (بما في ذلك الصداع الشديد المفاجئ، والارتباك، ومشكلة في الرؤية في إحدى العينين أو كلتيهما، وتنميل أو ضعف الوجه أو الذراع أو الساق عادة على جانب واحد، وارتخاء الوجه، وصعوبة في المشي، والدوار، وفقدان التوازن، وصعوبة في الكلام)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب شديد مع انخفاض عدد خلايا الدم الحمراء وضيق التنفس (فقر الدم الانحلالي)، وحده أو مصحوبًا بانخفاض تعداد الصفيحات الدموية، وتكدم غير طبيعي (قلة الصفيحات)، ومرض بالكلى يجعل كمية البول قليلة أو منعدمة (أعراض متلازمة انحلال الدم اليوريمية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الأخرى المعروفة لأوكساليبلاتن هي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>آثار شائعة جدًا (قد تؤثر على أكثر من فرد واحد بين كل ١٠ أفراد): </u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أن يؤثر أوكساليبلاتن على الأعصاب (اعتلال الأعصاب الطرفية). قد تشعر بوخز و/أو خدر في أصابع اليدين، أو أصابع القدمين، أو حول الفم، أو في الحلق، وقد يحدث ذلك أحيانًا مصحوبًا بتشنجات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُثير التعرض للبرودة، مثل فتح الثلاجة أو الإمساك بمشروب بارد، ظهور هذه الآثار في أغلب الأوقات. قد تجد أيضًا صعوبة في أداء المهام الدقيقة مثل تزرير الملابس. على الرغم من أن هذه الأعراض تختفي من تلقاء نفسها بالكامل في معظم الحالات، إلا أن هناك احتمال أن تستمر أعراض اعتلال الأعصاب الطرفية الحسي بعد نهاية العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعرض بعض الأشخاص لوخز وشعور يشبه الصدمة ينتقل إلى الذراعين أو الجذع عند ثني الرقبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; يمكن أن يتسبب أوكساليبلاتن أحيانًا في شعور مزعج في الحلق، خاصة عند البلع، ويعطي إحساسًا بضيق التنفس. يتم اختبار هذا الشعور عادة، إن حدث، أثناء التسريب أو خلال ساعات منه وقد يثير التعرض للبرودة هذا الشعور.</p><p dir="RTL">وعلى الرغم من كونه مزعجًا، إلا أنه لن يدوم طويلًا ويختفي دون الحاجة إلى أي علاج. قد يقرر طبيبك تغيير علاجك نتيجة لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; قد يسبب أوكساليبلاتن الإسهال، والغثيان الخفيف (الشعور بالرغبة في التقيؤ) والقيء؛ إلا أنه عادةً ما يعطيك طبيبك دواءً لمنع الغثيان قبل العلاج وقد يستمر لما بعد العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; يسبب أوكساليبلاتن انخفاضًا مؤقتًا في عدد خلايا الدم. قد يسبب انخفاض عدد خلايا الدم الحمراء فقر الدم (قلة خلايا الدم الحمراء)، أو نزيف أو تكدم غير طبيعي (نتيجة انخفاض عدد الصفيحات الدموية).</p><p dir="RTL">انخفاض عدد خلايا الدم البيضاء قد يجعلك عرضة للإصابة بالعدوى.</p><p dir="RTL">سيأخذ طبيبك عينة من الدم ليتأكد من أن لديك عددًا كافيًا من خلايا الدم قبل بدء العلاج وقبل كل دورة علاج تالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; شعور بعدم الراحة في موضع الحقن أو بالقرب منه أثناء التسريب،</p><p dir="RTL">&bull; حمى، تيبسات (رعاش)، تعب خفيف أو شديد، ألم بالجسم،</p><p dir="RTL">&bull; تغيرات في الوزن، نقص أو فقدان الشهية، اضطرابات التذوق، إمساك،</p><p dir="RTL">&bull; صداع، ألم بالظهر،</p><p dir="RTL">&bull; تورم الأعصاب المؤدية إلى عضلاتك، تصلب الرقبة، إحساس غير طبيعي باللسان من المحتمل أن يؤدي إلى تغيير طريقة الكلام، التهاب الفم/الغشاء المخاطي (تقرح الشفتين أو قرح الفم)،</p><p dir="RTL">&bull; ألم بالمعدة،</p><p dir="RTL">&bull; نزيف غير طبيعي بما في ذلك نزيف الأنف،</p><p dir="RTL">&bull; سعال، صعوبة في التنفس،</p><p dir="RTL">&bull; تفاعلات حساسية، طفح جلدي قد يكون أحمر اللون ومثير للحكة، تساقط خفيف للشعر (ثعلبة)،</p><p dir="RTL">&bull; تغير في اختبارات الدم بما في ذلك الاختبارات المرتبطة باضطرابات وظائف الكبد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>آثار شائعة (قد تؤثر على ما يصل إلى فرد واحد بين كل ١٠ أفراد):</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">&bull; عدوى نتيجة انخفاض عدد خلايا الدم البيضاء،</p><p dir="RTL">&bull; عدوى خطيرة بالدم بالإضافة إلى انخفاض عدد خلايا الدم البيضاء (الإنتان الناتج عن قلة العدلات)، وقد تكون هذه الحالة مميتة،</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء مصحوبًا بحمى تكون فيها درجة حرارة الجسم أكبر من ٣٨,٣ درجة مئوية أو حمى مطولة تكون فيها درجة حرارة الجسم أكبر من ٣٨ درجة مئوية لأكثر من ساعة (قلة العدلات الحموية)،</p><p dir="RTL">&bull; عسر الهضم وحرقة المعدة، زغطة، احمرار، دوار،</p><p dir="RTL">&bull; زيادة العرق واضطرابات الأظافر، تقشر الجلد،</p><p dir="RTL">&bull; ألم في الصدر،</p><p dir="RTL">&bull; اضطرابات الرئة وسيلان الأنف،</p><p dir="RTL">&bull; ألم المفاصل وألم العظام،</p><p dir="RTL">&bull; ألم عند التبول وتغيرات في وظائف الكلى، تغيرات في معدل التبول، جفاف،</p><p dir="RTL">&bull; وجود دم في البول/البراز، تورم الأوردة، جلطات في الرئة،</p><p dir="RTL">&bull; ضغط دم مرتفع،</p><p dir="RTL">&bull; اكتئاب وأرق،</p><p dir="RTL">&bull; التهاب الملتحمة ومشكلات في الرؤية،</p><p dir="RTL">&bull; انخفاض مستويات الكالسيوم في الدم،</p><p dir="RTL">&bull; حوادث السقوط.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>آثار غير شائعة (قد تصيب ما يصل إلى فرد واحد بين كل ١٠٠ فرد):</u> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull; عدوى خطيرة بالدم (إنتان)، والتي قد تكون مميتة،</p><p dir="RTL">&bull; انسداد الأمعاء أو تورمها،</p><p dir="RTL">&bull; توتر الأعصاب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>آثار نادرة (قد تصيب ما يصل إلى فرد واحد من بين كل ١٠٠٠ فرد):</u></strong></p><p dir="RTL">&bull; فقدان السمع،</p><p dir="RTL">&bull; تندب الرئتين وزيادة سمكهما مع صعوبات في التنفس، أحيانًا تكون مميتة (المرض الرئوي الخلالي)،</p><p dir="RTL">&bull; فقدان الرؤية قصير الأمد القابل للعكس</p><p dir="RTL">&bull; نزيف أو تكدم غير متوقع نتيجة الجلطات الدموية المنتشرة على نطاق واسع في الأوعية الدموية الصغيرة في الجسم (التخثر المنتشر داخل الأوعية الدموية)، والذي قد يكون مميتًا.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>آثار نادرة جدًا (قد تصيب ما يصل إلى فرد واحد من بين كل ١٠٠٠٠ فرد)</u></strong></p><ul><li dir="RTL">وجود جسيمات دموية أو بنية داكنة بلون القهوة في قيئك،</li><li dir="RTL">مرض بالكلى يجعل كمية البول قليلة أو منعدمة (أعراض فشل كلوي حاد).</li><li dir="RTL">اضطرابات وعائية بالكبد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>غير معروفة (معدل التكرار لا يمكن تقديره من البيانات المتاحة)</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الناتج عن الحساسية (التهاب الأوعية الدموية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل مناعي ذاتي يؤدي إلى انخفاض عدد جميع خطوط خلايا الدم (قلة الكريات الشاملة الناتج عن تفاعل مناعي ذاتي) قلة الكريات الشاملة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى خطيرة بالدم وضغط دم منخفض (صدمة إنتانية)، والتي قد تكون مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختلاج (اهتزاز الجسم بشكل خارج عن السيطرة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج الحلق مما يتسبب في صعوبة في التنفس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن حدوث تعب شديد مع انخفاض عدد خلايا الدم الحمراء وضيق التنفس (فقر الدم الانحلالي)، وحده أو مصحوبًا بانخفاض تعداد الصفيحات الدموية ومرض بالكلى يجعل كمية البول قليلة أو منعدمة (أعراض متلازمة انحلال الدم اليوريمية)، وقد تكون هذه الأعراض مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظم غير طبيعي لضربات القلب (إطالة فترة QT)، والذي يمكن رؤيته في مخطط كهربية القلب (ECG)، وقد تكون هذه الحالة مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزمة القلبية (احتشاء عضلة القلب)، أو شعور بالألم، أو الانزعاج في الصدر (الذبحة الصدرية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المريء - وهو الأنبوب الذي يربط بين فمك ومعدتك &ndash; مما يسبب ألمًا وصعوبة في البلع (الالتهاب المريئي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات وتورمها، مصحوبًا بضعف وحمى وبول لونه أحمر يميل إلى بني (أعراض لحالة يحدث بها تلف العضلات تسمى انحلال الربيدات)، وقد تكون هذه الحالة مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن، أو غثيان، أو قيء دموي أو قيء يشبه &quot;ثفل القهوة&quot;، أو براز داكن اللون/يشبه القطران (أعراض قرحة معدية معوية، مصحوبة بنزيف أو انثقاب محتمل)، وقد تكون هذه الحالة مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تدفق الدم إلى الأمعاء (إقفار الأمعاء)، وقد تكون هذه الحالة مميتة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطر الإصابة بسرطانات جديدة. أبلغ عن ابيضاض الدم، وهو أحد أشكال سرطان الدم، لدى المرضى بعد تناول أوكساليبلاتن بالتزامن مع بعض الأدوية الأخرى. تحدث إلى طبيبك بشأن احتمالية زيادة خطر الإصابة بهذا النوع من السرطان عند تناول أوكساليبلاتن وبعض الأدوية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقيدات الكبد غير السرطانية غير الطبيعية (فرط التنسج العقدي البؤري).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة بشأنها. يتضمن ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;دول الخليج الأخرى:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يخزّن في درجة حرارة أقل من ٣٠ درجة مئوية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال. تُحفظ القارورة في العبوة الكرتونية الخارجية من أجل حمايتها من الضوء.&nbsp; لا تقم بتجميده.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية والملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد تخفيفه، ينبغي استخدام المستحضر المعد للتسريب فورًا.&nbsp; فيما يخص الاستقرار الكيميائي والفيزيائي أثناء الاستخدام، تم إثبات استمراره لمدة ٢٤ ساعة عند الحفظ في درجة حرارة تتراوح بين درجتين مئويتين و٨ درجات مئوية، ولمدة ٦ ساعات عند الحفظ في درجة حرارة تبلغ ٢٥ درجة مئوية. إذا لم يستخدم الدواء فورًا، فإن مسؤولية مدة وظروف التخزين أثناء فترة الاستخدام ستقع على عاتق المستخدم ولن تزيد هذه المدة عادةً عن ٢٤ ساعة عند الحفظ في درجة حرارة تتراوح بين درجتين مئويتين و٨ درجات مئوية.</p><p dir="RTL">ينبغي ألا يلامس أوكساليبلاتن العينين أو الجلد. إذا حدث أي انسكاب عن طريق الخطأ، فأخبر الطبيب أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند انتهاء التسريب، سيتم التخلص من أوكساليبلاتن بعناية من قِبل الطبيب أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أوكساليبلاتن. &nbsp;</p><p dir="RTL">يحتوي المل الواحد من ركازة تحضير محلول للتسريب على ٥ ملجم أوكساليبلاتن.&nbsp;</p><p dir="RTL">تحتوي الـ١٠ مل من ركازة تحضير محلول للتسريب على ٥٠ ملجم أوكساليبلاتن.</p><p dir="RTL">تحتوي الـ٢٠ مل من ركازة تحضير محلول للتسريب على ١٠٠ ملجم أوكساليبلاتن.</p><p dir="RTL">تحتوي الـ٤٠ مل من ركازة تحضير محلول للتسريب على ٢٠٠ ملجم أوكساليبلاتن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي حمض الطرطريك وهيدروكسيد الصوديوم وماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي أوكساليبلاتن هوسبيرا في صورة محلول ركازة للتسريب (محلول مركز يتم تخفيفه لإعداد محلول يمكن إعطاؤه في صورة تسريب بطيء بالتنقيط). يحتوي كل ملليلتر (مل) من المحلول على ٥ مليجرام (ملجم) من أوكساليبلاتن. وهو محلول صاف عديم اللون معبأ في حاويات زجاجية تسمى قوارير، تحتوي على ٥٠ ملجم (١٠ مل)، و١٠٠ ملجم (٢٠ مل)، و٢٠٠ ملجم (٤٠ مل) من أوكساليبلاتن. تُغلف القوارير ببلاستيك واق لتقليل خطر الانسكاب إذا تعرضت القوارير للكسر - ويشار إليها بـONCO-TAIN&reg;. تتوفر القوارير في عبوات فردية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تخفيف المحلول بعد ذلك في محلول جلوكوز ٥ ٪ ويمكن إعطاؤه في صورة تسريب بالتنقيط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق </strong></p><p>Hospira UK Limited</p><p>Horizon</p><p>Honey Lane</p><p>Hurley</p><p>Maidenhead</p><p>SL6 6RJ</p><p>UK، المملكة المتحدة</p><p>&nbsp;</p><p><strong>المصنع:</strong></p><ul><li>Zydus Hospira Oncology Private Limited, Plot No.3, Pharmez - Special Economic Zone, Sarkhej Bavla Highway, (N.H, No. 8A), Matoda, Taluka Sanand, District Ahmedabad &ndash; 382213,, Ahmedabad, India، الهند</li></ul><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/كانون الأول ٢٠٢٠
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oxaliplatin Hospira 5 mg/ml Concentrate for Solution for Infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of concentrate for solution for infusion contains 5 mg oxaliplatin.

10 ml of concentrate for solution for infusion contains 50 mg of oxaliplatin.
20 ml of concentrate for solution for infusion contains 100 mg of oxaliplatin.
40 ml of concentrate for solution for infusion contains 200 mg of oxaliplatin.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin in combination with 5-fluorouracil (5‑FU) and folinic acid (FA) is indicated for:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjuvant treatment of stage III (Duke&rsquo;s C) colon cancer after complete resection of primary tumour.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of metastatic colorectal cancer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicinal products used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicinal products, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area (see section 6.6).</p><p>&nbsp;</p><p><strong>Posology</strong></p><p><strong>&nbsp;</strong></p><p>FOR ADULTS ONLY</p><p>&nbsp;</p><p>The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m&sup2; intravenously repeated every two weeks for 12 cycles (6 months).</p><p>&nbsp;</p><p>The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85&nbsp;mg/m&sup2; intravenously repeated every 2 weeks until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Dosage given should be adjusted according to tolerability. (see section 4.4).</p><p>&nbsp;</p><p><strong>Oxaliplatin should always be administered before fluoropyrimidines, i.e. 5-fluorouracil (5‑FU).</strong></p><p>&nbsp;</p><p>Oxaliplatin is administered as a 2- to 6-hour intravenous infusion in 250 to 500 ml of glucose 5 % (50 mg/ml) solution to give a concentration between 0.2&nbsp;mg/ml and 0.70&nbsp;mg/ml; 0.70&nbsp;mg/ml is the highest concentration in clinical practice for an oxaliplatin dose of 85&nbsp;mg/m<sup>2</sup>.</p><p>&nbsp;</p><p>Oxaliplatin has mainly been used in combination with continuous infusion 5‑fluorouracil &nbsp;(5 FU) based regimens. For the two-weekly treatment schedule 5‑fluorouracil regimens (5 FU) combining bolus and continuous infusion were used.</p><p>&nbsp;</p><p>Special Populations</p><p>&nbsp;</p><p><em><u>Renal impairment:</u></em></p><p>&nbsp;</p><p>Oxaliplatin must not be administered in patients with severe renal impairment (see</p><p>sections 4.3 and 5.2).</p><p>&nbsp;</p><p>In patients with mild to moderate renal impairment, the recommended dose of oxaliplatin is 85 mg/m<sup>2</sup> (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em><u>Hepatic insufficiency:</u></em></p><p>&nbsp;</p><p>In a phase I study including patients with several levels of hepatic impairment, frequency and severity of hepatobiliary disorders appeared to be related to progressive disease and impaired liver function tests at baseline. &nbsp;No specific dose adjustment for patients with abnormal liver function tests was performed during clinical development.</p><p>&nbsp;</p><p><em><u>Elderly patients:</u></em></p><p>&nbsp;</p><p>No increase in severe toxicities was observed when oxaliplatin was used as a single agent or in combination with 5-fluorouracil (5 FU) in patients over the age of 65. In consequence no specific dose adaptation is required for elderly patients.</p><p><u>&nbsp;</u></p><p><em><u>Paediatric patients:</u></em></p><p><u>&nbsp;</u></p><p>There is no relevant indication for use of oxaliplatin in children. The effectiveness of oxaliplatin single agent in the paediatric populations with solid tumours has not been established (see section 5.1).</p><p><u>&nbsp;</u></p><p><strong>Method of administration</strong></p><p>&nbsp;</p><p>Oxaliplatin is administered by intravenous infusion.</p><p>&nbsp;</p><p>The administration of oxaliplatin does not require hyperhydration.</p><p>&nbsp;</p><p>Oxaliplatin diluted in 250 to 500 ml of glucose 5% (50 mg/ml) solution to give a concentration not less than 0.2 mg/ml must be infused either via a central venous line or a peripheral vein over 2 to 6 hours. Oxaliplatin infusion must always precede the administration of 5‑fluorouracil (5 FU).</p><p>&nbsp;</p><p>In the event of extravasation, administration must be discontinued immediately.</p><p>&nbsp;</p><p><strong>Instructions for use: </strong></p><p>&nbsp;</p><p>Oxaliplatin must be diluted before use. Only glucose diluent 5 % (50 mg/ml) is to be used to dilute the concentrated solution for infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oxaliplatin is contraindicated in patients who

- 	have a known history of hypersensitivity to oxaliplatin or to any of the excipients listed in section 6.1.

- 	are breast feeding.

-         have myelosuppression prior to starting first course, as evidenced by baseline neutrophils <2x109/l and/or platelet count of <100x109/l.

-         have a peripheral sensory neuropathy with functional impairment prior to first course.

-         have a severely impaired renal function (creatinine clearance less than 30 ml/min) (see section 5.2).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin should only be used in specialised departments of oncology and should be administered under the supervision of an experienced oncologist.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p><strong><u>&nbsp;</u></strong></p><p>Patients with mild to moderate renal impairment should be closely monitored for adverse reactions and dose adjusted according to toxicity (see section 5.2).</p><p>&nbsp;</p><p><strong>Hypersensitivity reactions</strong></p><p>&nbsp;</p><p>Special surveillance should be ensured for patients with a history of allergic manifestations to other products containing platinum. In case of anaphylactic manifestations the infusion should be interrupted immediately and an appropriate symptomatic treatment started. Re‑administration of oxaliplatin to such patients is contraindicated. Cross reactions, sometimes fatal, have been reported with all platinum compounds.</p><p>&nbsp;</p><p><strong>Extravasation</strong></p><p><strong><u>&nbsp;</u></strong></p><p>In case of oxaliplatin extravasation, the infusion must be stopped immediately and usual local symptomatic treatment initiated.</p><p>&nbsp;</p><p><strong>Neurological symptoms </strong></p><p>Neurological toxicity of oxaliplatin should be carefully monitored, especially if co-administered with other medicinal products with specific neurological toxicity. A neurological examination should be performed before each administration and periodically thereafter.</p><p>&nbsp;</p><p>For patients who develop acute laryngopharyngeal dysaesthesia (see section 4.8), during or within the hours following the 2-hour infusion, the next oxaliplatin infusion should be administered over 6 hours.</p><p>&nbsp;</p><p><strong>Peripheral neuropathy</strong></p><p><strong><u>&nbsp;</u></strong></p><p>If neurological symptoms (paraesthesia, dysaesthesia) occur, the following recommended oxaliplatin dosage adjustment should be based on the duration and severity of these symptoms:</p><p>&nbsp;</p><p>- If symptoms last longer than seven days and are troublesome, the subsequent oxaliplatin dose should be reduced from 85 to 65 mg/m<sup>2 </sup>(metastatic setting) or 75&nbsp;mg/m<sup>2 </sup>(adjuvant setting).</p><p>&nbsp;</p><p>-&nbsp; If paraesthesia without functional impairment persists until the next cycle, the subsequent oxaliplatin dose should be reduced from 85 to 65 mg/m<sup>2 </sup>(metastatic setting) or 75 mg/m<sup>2 </sup>(adjuvant setting).</p><p>&nbsp;</p><p>- If paraesthesia with functional impairment persists until the next cycle, oxaliplatin should be discontinued.</p><p>&nbsp;</p><p>- If these symptoms improve following discontinuation of oxaliplatin therapy, resumption of therapy may be considered.</p><p>&nbsp;</p><p>Patients should be informed of the possibility of persistent symptoms of peripheral sensory neuropathy after the end of the treatment. Localized moderate paraesthesias or paraesthesias that may interfere with functional activities can persist after up to 3 years following treatment cessation in the adjuvant setting.</p><p>&nbsp;</p><p><em><u>Reversible Posterior Leukoencephalopathy Syndrome</u></em><u> (RPLS)</u></p><p><u>&nbsp;</u></p><p>Cases of Reversible Posterior Leukoencephalopathy Syndrome (RPLS also known as PRES, Posterior Reversible Encephalopathy Syndrome) have been reported in patients receiving oxaliplatin in combination chemotherapy. RPLS is a rare, reversible, rapidly evolving neurological condition, which can include seizure, hypertension, headache, confusion, blindness, and other visual and neurological disturbances (see section 4.8). Diagnosis of RPLS is based upon confirmation by brain imaging, preferably MRI (Magnetic Resonance Imaging).</p><p>&nbsp;</p><p><em><u>Nausea, vomiting, diarrhoea, dehydration, and haematologic changes</u></em></p><p><em><u>&nbsp;</u></em></p><p>Gastrointestinal toxicity, which manifests as nausea and vomiting, warrants prophylactic and/or therapeutic anti-emetic therapy (see section 4.8).</p><p>&nbsp;</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-FU.</p><p>&nbsp;</p><p>Cases of intestinal ischaemia, including fatal outcomes, have been reported with oxaliplatin treatment. In case of intestinal ischaemia, oxaliplatin treatment should be discontinued and appropriate measures initiated. (see section 4.8).</p><p>&nbsp;</p><p>If haematological toxicity occurs (neutrophils ˂ 1.5 x 10<sup>9</sup>/l or platelets ˂ 50 x 10<sup>9</sup>/l), administration of the next course of therapy should be postponed until haematological values return to acceptable levels. A full blood count with white cell differential should be performed prior to start of therapy and before each subsequent course.</p><p>&nbsp;</p><p>Patients must be adequately informed of the risk of diarrhoea/emesis, mucositis/stomatitis and neutropenia after oxaliplatin <s>/</s>5-fluorouracil (5-FU) administration so that they can urgently contact their treating physician for appropriate management. &nbsp;</p><p>&nbsp;</p><p>If mucositis/stomatitis occurs with or without neutropenia, the next treatment should be delayed until recovery from mucositis/stomatitis to grade 1 or less and/or until the neutrophil count is &ge; 1.5 x 10<sup>9</sup>/l.</p><p>&nbsp;</p><p>For oxaliplatin combined with 5-fluorouracil (5-FU) (with or without folinic acid (FA)), the usual dose adjustments for 5-fluorouracil (5-FU) associated toxicities should apply.</p><p>&nbsp;</p><p>If grade 4 diarrhoea, grade 3-4 neutropenia (neutrophils &lt; 1.0 x 10<sup>9</sup>/l), febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection with an absolute neutrophil count &lt; 1.0 x 10<sup>9</sup>/l, a single temperature of &gt; 38.3&deg;C or a sustained temperature of &gt; 38&deg;C for more than one hour), or grade 3-4 thrombocytopenia (platelets <u>&lt;</u> 50 x 10<sup>9</sup>/l) occur, the dose of oxaliplatin should be reduced from 85 to 65 mg/m<sup>2</sup> (metastatic setting) or 75 mg/m<sup>2</sup> (adjuvant setting), in addition to any 5-FU dose reductions required.</p><p>&nbsp;</p><p><strong>Pulmonary</strong><strong> </strong></p><p><strong>&nbsp;</strong></p><p>In the case of unexplained respiratory symptoms such as non-productive cough, dyspnoea, crackles or radiological pulmonary infiltrates, oxaliplatin should be discontinued until further pulmonary investigations exclude an interstitial lung disease or pulmonary fibrosis (see section 4.8).</p><p>&nbsp;</p><p><strong>Blood disorders</strong></p><p><strong>&nbsp;</strong></p><p>Haemolytic-uraemic syndrome (HUS) is a life-threatening side effect (frequency not known).</p><p>&nbsp;</p><p>Oxaliplatin should be discontinued at the first signs of any evidence of microangiopathic haemolytic anaemia, such as rapidly falling haemoglobin with concomitant thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.</p><p>&nbsp;</p><p>Disseminated intravascular coagulation (DIC), including fatal outcomes, has been reported in association with oxaliplatin treatment. If DIC is present, oxaliplatin treatment should be discontinued and appropriate treatment should be administered. (see section 4.8).</p><p>&nbsp;</p><p><strong>QT prolongation</strong></p><p><strong><u>&nbsp;</u></strong></p><p>QT prolongation may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes, which can be fatal (see section 4.8). The QT interval should be closely monitored on a regular basis before and after administration of oxaliplatin. Caution should be exercised in patients with a history or a predisposition for prolongation of QT, those who are taking medicinal products known to prolong QT interval, and those with electrolyte disturbances such as hypokalemia, hypocalcaemia, or hypomagnesaemia. In case of QT prolongation, oxaliplatin treatment should be discontinued. (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><strong>Rhabdomyolysis</strong></p><p><strong><u>&nbsp;</u></strong></p><p>Rhabdomyolysis has been reported in patients treated with oxaliplatin, including fatal outcomes. In case of muscle pain and swelling, in combination with weakness, fever or darkened urine, oxaliplatin treatment should be discontinued. If rhabdomyolysis is confirmed, appropriate measures should be taken. Caution is recommended if medicinal products associated with rhabdomyolysis are administered concomitantly with oxaliplatin. (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><strong>Gastrointestinal ulcer/ Gastrointestinal haemorrhage and perforation</strong></p><p><strong><u>&nbsp;</u></strong></p><p>Oxaliplatin treatment can cause gastrointestinal ulcer and potential complications, such as duodenal ulcer haemorrhage and perforation, which can be fatal. In case of duodenal ulcer, oxaliplatin treatment should be discontinued and appropriate measures taken. (see section 4.8)</p><p>&nbsp;</p><p><strong>Hepatic</strong></p><p><strong><u>&nbsp;</u></strong></p><p>In case of abnormal liver function test results or portal hypertension which does not obviously result from liver metastases, very rare cases of drug‑induced hepatic vascular disorders should be considered.</p><p>&nbsp;</p><p><strong>Immunosuppressant Effects/Increased Susceptibility to Infections</strong></p><p>&nbsp;</p><p>Administration of live or live attenuated vaccines in patients immunocompromised by chemotherapeutic agents, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving oxaliplatin. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p><p>&nbsp;</p><p>Pregnancy</p><p>&nbsp;</p><p>For use in pregnant women, see section 4.6.</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>Genotoxic effects were observed with oxaliplatin in the preclinical studies. Therefore male patients treated with oxaliplatin are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because oxaliplatin may have an anti-fertility effect, which could be irreversible.</p><p>Women should not become pregnant during treatment with oxaliplatin and should use an effective method of contraception (see section 4.6).</p><p>&nbsp;</p><p>Peritoneal hemorrhage may occur when oxaliplatin is administered by intraperitoneal route (off-label route of administration).</p><p>&nbsp;</p><p><strong><u>Excipient information</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per vial. Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients who have received a single dose of 85 mg/m<sup>2</sup> of oxaliplatin, immediately before administration of 5‑fluorouracil (5-FU), no change in the level of exposure to 5-fluorouracil (5-FU) has been observed.</p><p><em>&nbsp;</em></p><p><em>In vitro</em>, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: erythromycin, salicylates, granisetron, paclitaxel, and sodium valproate.</p><p>&nbsp;</p><p>Caution is advised when oxaliplatin treatment is co-administered with other medicinal products known to cause QT interval prolongation. In case of combination with such medicinal products, the QT interval should be closely monitored (see section 4.4). Caution is advised when oxaliplatin treatment is administered concomitantly with other medicinal products known to be associated with rhabdomyolysis. (see section 4.4).</p><p>&nbsp;</p><p>Vaccination with live or live-attenuated vaccine should be avoided in patients receiving oxaliplatin (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>&nbsp;</p><p>To date there is no available information on safety of use in pregnant women. In animal studies, reproductive toxicity was observed. Consequently, oxaliplatin is not recommended during pregnancy and in women of childbearing potential not using contraceptive measures.</p><p>&nbsp;</p><p>The use of oxaliplatin should only be considered after suitably appraising the patient of the risk to the foetus and with the patient&rsquo;s consent.</p><p>&nbsp;</p><p>Appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women and 6 months for men.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&nbsp;</p><p>Excretion in breast milk has not been studied. Breast-feeding is contra-indicated during oxaliplatin therapy.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>&nbsp;</p><p>Oxaliplatin may have an anti-fertility effect (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. &nbsp;However oxaliplatin treatment resulting in an increase risk of dizziness, nausea and vomiting, and other neurological symptoms that affect gait and balance may lead to a minor or moderate influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), may affect patients&rsquo; ability to drive and use machines. Therefore, patients should be warned of the potential effect of these events on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse events of oxaliplatin in combination with 5‑fluorouracil/(5‑FU)/folinic acid (FA), were gastrointestinal (diarrhoea, nausea, vomiting and mucositis), haematological (neutropenia, thrombocytopenia) and neurological (acute and dose cumulative peripheral sensory neurophathy). Overall, these events were more frequent and severe with oxaliplatin and 5-fluorouracil (5-FU)/folinic acid (FA) combination than with 5‑fluorouracil (5-FU)/folinic acid (FA) alone.</p><p>&nbsp;</p><p>The frequencies reported in the table below are derived from clinical trials in the metastatic and adjuvant settings (having included 416 and 1108 patients respectively in the oxaliplatin</p><p>+ 5‑fluorouracil (5FU/folinic acid (FA) arm) and from post-marketing experience.</p><p>&nbsp;</p><p>Frequencies in this table are defined using the following convention: very common (&ge;1/10) common (&ge; 1/100, &nbsp;&lt; 1/10), uncommon (&ge; 1/1000, &nbsp;&lt; 1/100), rare (&ge; 1/10000, &nbsp;&lt; 1/1000), very rare (&lt; 1/10000) not known (cannot be estimated from the available data).</p><p>Further details are given after the table.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:97%"><tbody><tr><td colspan="3"><p><strong>Infections and infestations*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Infection</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Rhinitis, Upper respiratory tract infection, Neutropenic sepsis</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Uncommon</p></td><td><p>Sepsis<sup>2</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Septic shock (including fatal outcomes)</p></td></tr><tr><td colspan="3"><p><strong>Blood and lymphatic system disorders*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Anaemia, Neutropenia, Thrombocytopenia, Leukopenia, Lymphopenia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Febrile neutropenia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Immunoallergic thrombocytopenia, Haemolytic anaemia, Disseminated intravascular coagulation (DIC), including fatal outcomes<sup>3</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Secondary leukaemia, Haemolytic-uraemic syndrome, Autoimmune pancytopenia, Pancytopenia</p></td></tr><tr><td colspan="3"><p><strong>Immune system disorders*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Allergy/allergic reaction<sup>2</sup> &nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Anorexia, Hyperglycaemia, Hypokalaemia, Hypernatraemia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Dehydration, Hypocalcaemia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Uncommon</p></td><td><p>Metabolic acidosis</p></td></tr><tr><td colspan="3"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Depression, Insomnia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Uncommon</p></td><td><p>Nervousness</p></td></tr><tr><td colspan="3"><p><strong>Nervous system disorders*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Peripheral sensory neuropathy, Sensory disturbance, Dysgeusia, Headache</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Dizziness, Motor neuritis, Meningism</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Dysarthria, Reversible Posterior Leukoencephalopathy Syndrome (RPLS or PRES)<sup>3</sup>&nbsp; &nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Ischemic or haemorrhagic cerebrovascular disorder, Convulsion</p></td></tr><tr><td colspan="3"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Conjunctivitis, Visual disturbance</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Visual acuity reduced transiently, Visual field disturbances, Optic neuritis, &nbsp;&nbsp;Transient vision loss reversible, following therapy discontinuation</p></td></tr><tr><td colspan="3"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Uncommon</p></td><td><p>Ototoxicity</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Deafness</p></td></tr><tr><td colspan="3"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Acute coronary syndrome<sup>4</sup>, QT Prolongation<sup>5</sup></p></td></tr><tr><td colspan="3"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Haemorrhage, Flushing, Deep vein thrombosis, Hypertension</p></td></tr><tr><td colspan="3"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Dyspnoea, Cough, Epistaxis</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Hiccups, Pulmonary embolism</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Interstitial lung disease (sometimes fatal), Pulmonary fibrosis<sup>3</sup>&nbsp; &nbsp;&nbsp;&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Laryngospasm, Pneumonia and bronchopneumonia (including fatal outcomes)</p></td></tr><tr><td colspan="3"><p><strong>Gastrointestinal disorders*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Nausea, Diarrhoea, Vomiting, Stomatitis/Mucositis, Abdominal pain, Constipation</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Dyspepsia, Gastroesophageal reflux, Gastrointestinal haemorrhage, Rectal haemorrhage</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Uncommon</p></td><td><p>Ileus, Intestinal obstruction</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Rare</p></td><td><p>Colitis including <em>Clostridium difficile</em> diarrhoea, Pancreatitis</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Intestinal ischaemia (including fatal outcomes)<sup>3</sup>, Gastrointestinal ulcer and perforation (which can be fatal)<sup>3</sup>, Oesophagitis</p></td></tr><tr><td colspan="3"><p><strong>Hepato-biliary disorders*</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Rare</p></td><td><p>Liver sinusoidal obstruction syndrome (also known as veno-occlusive disease of liver)<sup>6</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Focal nodular hyperplasia</p></td></tr><tr><td colspan="3"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Skin disorder, Alopecia</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Skin exfoliation (i.e. Hand and Foot syndrome), Rash erythematous, Rash, Hyperhidrosis, Nail disorder</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Hypersensitivity vasculitis</p></td></tr><tr><td colspan="3"><p><strong>Musculo-skeletal and connective tissue disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Back pain</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Arthralgia, Bone pain</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Not Known<sup>1</sup></p></td><td><p>Rhabdomyolysis (including fatal outcomes)<sup>3</sup></p></td></tr><tr><td colspan="3"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Haematuria, Dysuria, Micturition frequency abnormal</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Rare</p></td><td><p>Acute tubular necrosis, Acute interstitial nephritis, Acute renal failure</p></td></tr><tr><td colspan="3"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Fatigue, Fever<sup>7</sup>, Asthenia, Pain, Injection site reaction<sup>8</sup>, Rigors</p></td></tr><tr><td colspan="3"><p><strong>Investigations</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very Common</p></td><td><p>Hepatic enzyme increase, Blood alkaline phosphatase increase, Blood bilirubin increase, Blood lactate dehydrogenase increase, Weight increase (adjuvant setting)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Blood creatinine increase, Weight decrease (metastatic setting)</p></td></tr><tr><td colspan="3"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Common</p></td><td><p>Fall</p></td></tr><tr><td colspan="3"><p><strong>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>See detailed section below</p><p><sup>1</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-marketing experience with frequency unknown</p><p><sup>2</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Very common allergies/allergic reactions, occurring mainly during infusion, sometimes fatal. Common allergic reactions include skin rash particularly urticaria, conjunctivitis, and rhinitis. Common anaphylactic or anaphylactoid reactions, include bronchospasm, angioeodema, hypotension, sensation of chest pain and anaphylactic shock. Delayed hypersensitivity has also been reported with oxaliplatin hours or even days after the infusion.</p><p><strong><sup>3</sup></strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See section 4.4</p><p><sup>4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</sup>Acute coronary syndrome, including myocardial infarction and coronary arteriospasm and angina pectoris in patients treated with oxaliplatin in combination with 5-FU and bevacizumab.</p><p><sup>5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</sup>QT prolongation, which may lead to ventricular arrhythmias including Torsade de &nbsp;&nbsp;&nbsp;&nbsp;Pointes, which may be fatal (see section 4.4).</p><p><sup>6</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Or pathological manifestations related to such liver disorder, including peliosis hepatis, nodular regenerative hyperplasia, perisinusoidal fibrosis. Clinical manifestations may be portal hypertension and/or increased transaminases</p><p><sup>7</sup><strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>Very common fever, rigors (tremors), either from infection (with or without febrile neutropenia) or possibly from immunological mechanism.</p><p><sup>8</sup><strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>Injection site reactions including local pain, redness, swelling and thrombosis have been reported. &nbsp;Extravasation may also result in local pain and inflammation which may be severe and lead to complications including necrosis, especially when oxaliplatin is infused through a peripheral vein (see section 4.4).</p><p><sup>&nbsp;</sup></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Blood and lymphatic system disorders</strong></p><p>&nbsp;</p><p>Incidence by patient (%), by grade</p><table border="1" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Oxaliplatin/5-FU/FA</strong></p><p><strong>85 mg/m<sup>2 </sup>every 2 weeks</strong></p></td><td colspan="3" style="vertical-align:top"><p>Metastatic setting</p></td><td colspan="3" style="vertical-align:top"><p>Adjuvant setting</p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p>gr 3</p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p><strong>gr 3</strong></p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>82.2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>75.6</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>71.4</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>78.9</p></td><td style="vertical-align:top"><p>28.8</p></td><td style="vertical-align:top"><p>12.3</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>71.6</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>77.4</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic sepsis</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.4</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Infections and infestations</strong></p><p><strong>&nbsp;</strong></p><p><strong>Incidence by patients (%)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Oxaliplatin and 5-FU/FA 85 mg/m<sup>2</sup> </strong></p><p>every 2 weeks</p></td><td style="vertical-align:top"><p>Metastatic setting</p></td><td style="vertical-align:top"><p>Adjuvant setting</p></td></tr><tr><td style="vertical-align:top"><p>All grades</p></td><td style="vertical-align:top"><p>All grades</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis (including sepsis and neutropenic sepsis)</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1.7</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><strong>&nbsp;</strong></p><p><strong>Immune system disorders</strong></p><p><em>&nbsp;</em></p><p><strong>Incidence of allergic reactions by patient (%), by grade</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Oxaliplatin/5-FU/FA</strong></p><p><strong>85 mg/m</strong><strong><sup>2 </sup></strong><strong>every 2 weeks</strong></p></td><td colspan="3" style="vertical-align:top"><p>Metastatic setting</p></td><td colspan="3" style="vertical-align:top"><p>Adjuvant setting</p></td></tr><tr><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p><strong>gr 3</strong></p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p>gr 3</p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td></tr><tr><td style="vertical-align:top"><p>Allergic reactions /Allergy</p></td><td style="vertical-align:top"><p>9.1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>0.6</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Nervous system disorders</p><p>&nbsp;</p><p>The dose limiting toxicity of oxaliplatin is neurological. &nbsp;It involves a sensory peripheral neuropathy characterised by dysaesthesia and/or parasthesia of the extremities with or without cramps, often triggered by the cold. &nbsp;These symptoms occur in up to 95% of patients treated. &nbsp;The duration of these symptoms, which usually regress between courses of treatment, increases with the number of treatment cycles.</p><p>&nbsp;</p><p>The onset of pain and/or a functional disorder are indications, depending on the duration of the symptoms, for dose adjustment, or even treatment discontinuation (see section 4.4).</p><p>&nbsp;</p><p>This functional disorder includes difficulties in executing delicate movements and is a possible consequence of sensory impairment. The risk of occurrence of persistent symptoms for a cumulative dose of 850 mg/m&sup2; (10 cycles) is approximately 10% and 20% for a cumulative dose of 1020 mg/m&sup2; (12 cycles). &nbsp;</p><p>&nbsp;</p><p>In the majority of the cases, the neurological signs and symptoms improve or totally recover when treatment is discontinued. &nbsp;In the adjuvant setting of colon cancer, 6 months after treatment cessation, 87% of patients had no or mild symptoms. &nbsp;After up to 3 years of follow up, about 3% of patients presented either with persisting localized paraesthesias of moderate intensity (2.3%) or with paraesthesias that may interfere with functional activities (0.5%).</p><p>&nbsp;</p><p>Acute neurosensory manifestations (see section 5.3) have been reported. They start within hours of administration and often occur on exposure to cold. They usually present as transient paraesthesia, dysesthesia and hypoesthesia. &nbsp;An acute syndrome of pharyngolaryngeal dysesthesia occurs in 1% -2% of patients and is characterised by subjective sensations of dysphagia or dyspnoea/feeling of suffocation, without any objective evidence of respiratory distress (no cyanosis or hypoxia) or of laryngospasm or bronchospasm (no stridor or wheezing). Although antihistamines and bronchodilators have been administered in such cases, the symptoms are rapidly reversible even in the absence of treatment. Prolongation of the infusion helps to reduce the incidence of this syndrome (see section 4.4). &nbsp;Occasionally other symptoms that have been observed include jaw spasm/muscle spasms/muscle contractions-involuntary/muscle twitching/myoclonus, coordination abnormal/gait abnormal/ataxia/balance disorders, throat or chest tightness/pressure/discomfort/pain. In addition, cranial nerve dysfunctions may be associated with above mentioned events, or also occur as an isolated event such as ptosis, diplopia, aphonia/dysphonia/hoarseness, sometimes described as vocal cord paralysis, abnormal tongue sensation or dysarthria, sometimes described as aphasia, trigeminal neuralgia/facial pain/eye pain, decrease in visual acuity, visual field disorders.</p><p>&nbsp;</p><p>Other neurological symptoms such as dysarthria, loss of deep tendon reflex and Lhermitte&#39;s sign were reported during treatment with oxaliplatin. Isolated cases of optic neuritis have been reported.</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p>&nbsp;</p><p>Incidence by patient (%), by grade</p><table border="1" cellspacing="0" cellpadding="0" style="width:555px"><tbody><tr><td style="vertical-align:top"><p><strong>Oxaliplatin/5FU/FA 85 mg/m</strong><strong><sup>2 </sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>Metastatic setting</p></td><td colspan="3" style="vertical-align:top"><p>Adjuvant setting</p></td></tr><tr><td style="vertical-align:top"><p><strong>every 2 weeks</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p>gr 3</p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p></td><td style="vertical-align:top"><p><strong>gr 3</strong></p></td><td style="vertical-align:top"><p><strong>gr 4</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>69.9</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>73.7</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>60.8</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>56.3</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>49.0</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>47.2</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Mucositis / Stomatitis</p></td><td style="vertical-align:top"><p>39.9</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>42.1</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.1</p></td></tr></tbody></table><p>&nbsp;</p><p>Prophylaxis and/or treatment with potent antiemetic agents is indicated.</p><p>&nbsp;</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalaemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5‑fluorouracil (5-FU) (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority </em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote to oxaliplatin.</p><p>&nbsp;</p><p>In cases of overdose, exacerbation of adverse events can be expected.</p><p>&nbsp;</p><p>Monitoring of haematological parameters should be initiated and symptomatic treatment given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, platinum compounds.</p><p>&nbsp;</p><p>ATC code: L01XA 03</p><p>&nbsp;</p><p>Oxaliplatin is an antineoplastic active substance belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (&ldquo;DACH&rdquo;) and an oxalate group.</p><p>&nbsp;</p><p>Oxaliplatin is a single enantiomer, (<em>SP</em>-4-2)-[(1R,2<em>R</em>)-Cyclohexane-1,2-diamine-k<em>N</em>, k<em>N</em>&#39;] [ethanedioato(2-)-k<em>O</em><sup>1</sup>, k<em>O</em><sup>2</sup>] platinum.</p><p>&nbsp;</p><p>Oxaliplatin exhibits a wide spectrum of both <em>in vitro</em> cytotoxicity and <em>in vivo</em> antitumour activity in a variety of tumour model systems including human colorectal cancer models. Oxaliplatin also demonstrates <em>in vitro</em> and <em>in vivo</em> activity in various cisplatin resistant models.</p><p>&nbsp;</p><p>A synergistic cytotoxic action has been observed in combination with 5-fluorouracil both<em> in vitro</em> and <em>in vivo</em>.</p><p>&nbsp;</p><p>Mechanism of action</p><p>Studies on the mechanism of action of oxaliplatin, although not completely elucidated, show that the aqua-derivatives resulting from the biotransformation of oxaliplatin, interact with DNA to form both inter and intra-strand cross-links, resulting in the disruption of DNA synthesis leading to cytotoxic and antitumour effects.</p><p>&nbsp;</p><p>In patients with metastatic colorectal cancer, the efficacy of oxaliplatin (85mg/m<sup>2</sup> repeated every two weeks) combined with 5-fluorouracil/folinic acid (5-FU/FA) is reported in three clinical studies:</p><p>&nbsp;</p><p>- In front-line treatment, the 2-arm comparative phase III EFC2962 study randomized 420 patients either to 5-FU/FA alone (LV5FU2, N=210) or the combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=210)</p><p>&nbsp;</p><p>- In pretreated patients the comparative three-arms phase III study EFC4584 randomized 821 patients refractory to an irinotecan (CPT-11) + 5-FU/FA combination either to 5-FU/FA alone (LV5FU2, N=275), oxaliplatin single agent (N=275), or combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=271).</p><p>&nbsp;</p><p>- Finally, the uncontrolled phase II EFC2964 study included patients refractory to 5‑FU/FA alone, that were treated with the oxaliplatin and 5‑FU/FA combination (FOLFOX4, N=57).</p><p>&nbsp;</p><p>The two randomized clinical trials, EFC2962 in front-line therapy and EFC4584 in pretreated patients, demonstrated a significantly higher response rate and a prolonged progression free survival (PFS)/time to progression (TTP) as compared to treatment with 5‑FU/FA alone. In EFC 4584 performed in refractory pretreated patients, the difference in median overall survival (OS) between the combination of oxaliplatin and 5-FU/FA did not reach statistical significance.</p><p>&nbsp;</p><p>Response rate under FOLFOX4 versus LV5FU2</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Response rate, % (95% CI)</strong></p><p><strong>&nbsp;</strong></p><p><strong>independent radiological review ITT analysis</strong></p></td><td style="vertical-align:top"><p>LV5FU2</p></td><td style="vertical-align:top"><p><strong>FOLFOX4</strong></p></td><td style="vertical-align:top"><p><strong>Oxaliplatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>Single agent</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Front-line treatment</p><p>EFC2962</p><p>Response assessment every 8 weeks</p></td><td style="vertical-align:top"><p>22</p><p>(16-27)</p></td><td style="vertical-align:top"><p>49</p><p>(42-546)</p></td><td style="vertical-align:top"><p>NA*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>P value = 0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pretreated patients</p><p>EFC4584</p><p>(refractory to CPT-11 + 5FU/FA)</p><p>Response assessment every 6 weeks</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.7</p><p>(0.0-2.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11.1</p><p>(7.6-15.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.1</p><p>(0.2-3.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>P value &lt; 0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pretreated patients</p><p>EFC2964</p><p>(refractory to 5-FU/FA)</p><p>Response assessment every 12 weeks</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23</p><p>(13-36)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NA: Not Applicable</p><p>&nbsp;</p><p><strong>Median Progression Free Survival (PFS) / Median Time to Progression (TTP) FOLFOX4 versus LV5FU2</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Median PFS/TTP,</strong></p><p><strong>months (95% CI)</strong></p><p><strong>independent radiological review ITT analysis</strong></p></td><td style="vertical-align:top"><p>LV5FU2</p></td><td style="vertical-align:top"><p><strong>FOLFOX4</strong></p></td><td style="vertical-align:top"><p><strong>Oxaliplatin</strong></p><p><strong>Single agent</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Front-line treatment</p><p>EFC2962 (PFS)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>6.0</p><p>(5.5-6.5)</p></td><td style="vertical-align:top"><p>8.2</p><p>(7.2-8.8)</p></td><td style="vertical-align:top"><p>NA*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-rank P value = 0.0003</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pretreated patients</p><p>EFC4584 (TTP)</p><p>(refractory to CPT-11 + 5FU/FA)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.6</p><p>(1.8-2.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.3</p><p>(4.7-6.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.1</p><p>(1.6-2.7)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-rank P value &lt; 0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pretreated patients</p><p>EFC2964</p><p>(refractory to 5-FU/FA)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.1</p><p>(3.1-5.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NA: Not Applicable</p><p><strong>&nbsp;</strong></p><p>Median Overall Survival (OS) under FOLFOX4 versus LV5FU2</p><table border="1" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td style="vertical-align:top"><p><strong>Median OS,</strong></p><p><strong>months (95% CI)</strong></p><p><strong>ITT analysis</strong></p></td><td style="vertical-align:top"><p>LV5FU2</p></td><td style="vertical-align:top"><p><strong>FOLFOX4</strong></p></td><td style="vertical-align:top"><p><strong>Oxaliplatin</strong></p><p><strong>Single agent</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Front-line treatment</p><p>EFC2962</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>14.7</p><p>(13.0-18.2)</p></td><td style="vertical-align:top"><p>16.2</p><p>(14.7-18.2)</p></td><td style="vertical-align:top"><p>NA*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-rank P value = 0.12</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pretreated patients</p><p>EFC4584*</p><p>(refractory to CPT-11 + 5FU/FA)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.8</p><p>(7.3-9.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.9</p><p>(9.1-10.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.1</p><p>(7.2-8.7)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-rank P value = 0.09</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pretreated patients</p><p>EFC2964</p><p>(refractory to 5-FU/FA)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10.8</p><p>(9.3-12.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NA*</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NA : Not Applicable</p><p>&nbsp;</p><p>In pretreated patients (EFC4584), who were symptomatic at baseline, a higher proportion of those treated with oxaliplatin and 5-FU/FA experienced a significant improvement of their disease-related symptoms compared to those treated with 5‑FU/FA alone (27.7% vs 14.6% p= 0.0033).</p><p>&nbsp;</p><p>In non‑pretreated patients (EFC2962), no statistically significant difference between the two treatment groups was found for any of the quality of life dimensions. However, the quality of life scores were generally better in the control arm for measurement of global health status and pain and worse in the oxaliplatin arm for nausea and vomiting.</p><p>&nbsp;</p><p>In the adjuvant setting, the MOSA&Iuml;C comparative phase III study (EFC3313) randomised 2246 patients (899 stage II/Duke&rsquo;s B2 and 1347 stage III/Duke&rsquo;s C) further to complete resection of the primary tumour of colon cancer either to 5-FU/FA alone (LV5FU2), N=&nbsp;1123&nbsp;(B2/C = 448/675) or to combination of oxaliplatin and 5-FU/FA (FOLFOX4), N=&nbsp;1123&nbsp;(B2/C = 451/672).</p><p>&nbsp;</p><p>EFC 3313 3-year disease free survival (ITT analysis)* for the overall population</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Treatment arm</p></td><td style="vertical-align:top"><p><strong>LV5FU2</strong></p></td><td style="vertical-align:top"><p><strong>FOLFOX4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Percent 3-year disease free survival (95% CI)</strong></p></td><td style="vertical-align:top"><p>73.3</p><p>(70.6-75.9)</p></td><td style="vertical-align:top"><p>78.7</p><p>(76.2-81.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="2" style="vertical-align:top"><p>0.76</p><p>(0.64-0.89)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratified log rank test</strong></p></td><td colspan="2" style="vertical-align:top"><p>P = 0.0008</p></td></tr></tbody></table><p>* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median follow up 44.2 months (all patients followed for at least 3 years)</p><p>&nbsp;</p><p>The study demonstrated an overall significant advantage in 3-year disease free survival for the oxaliplatin and 5-FU/FA combination (FOLFOX4) over 5-FU/FA alone (LV5FU2).</p><p>&nbsp;</p><p>EFC 3313 3-year disease free survival (ITT analysis)* according &nbsp;of disease stage</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Patient stage</p></td><td colspan="2" style="vertical-align:top"><p>Stage II</p><p><strong>(Duke&rsquo;s B2)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Stage III</strong></p><p><strong>Duke&rsquo;s C</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment arm</strong></p></td><td style="vertical-align:top"><p>LV5FU2</p></td><td style="vertical-align:top"><p>FOLFOX4</p></td><td style="vertical-align:top"><p>LV5FU2</p></td><td style="vertical-align:top"><p>FOLFOX4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Percent 3-year disease free survival </strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p>84.3</p><p>(80.9-87.7)</p></td><td style="vertical-align:top"><p>87.4</p><p>(84.3-90.5)</p></td><td style="vertical-align:top"><p>65.8</p><p>(62.2-69.5</p></td><td style="vertical-align:top"><p>72.8</p><p>(69.4-76.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hazard ratio (95% CI)</strong></p></td><td colspan="2" style="vertical-align:top"><p>0.79</p><p>(0.57-1.09)</p></td><td colspan="2" style="vertical-align:top"><p>0.75</p><p>(0.62-0.90)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Log-rank test</strong></p></td><td colspan="2" style="vertical-align:top"><p>P = 0.151</p></td><td colspan="2" style="vertical-align:top"><p>P = 0.002</p></td></tr></tbody></table><p>* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median follow up 44.2 months (all patients followed for at least 3 years)</p><p><strong>&nbsp;</strong></p><p><strong>Overall Survival (ITT analysis):</strong></p><p>&nbsp;</p><p>At time of the analysis of the 3-year disease free survival, which was the primary endpoint of the MOSAIC trial, 85.1% of the patients were still alive in the FOLFOX4 arm versus 83.8% in the LV5FU2 arm. &nbsp;This translated into an overall reduction in mortality risk of 10% in favour of FOLFOX4 not reaching statistical significance (hazard ratio = 0.90). &nbsp;The figures were 92.2% versus 92.4% in the stage II (Duke&rsquo;s B2) sub-population (hazard ratio = 1.01) and 80.4% versus 78.1% in the stage III (Duke&rsquo;s C) sub-population (hazard ratio = 0.87), for FOLFOX4 and LV5FU2, respectively.</p><p>&nbsp;</p><p>Oxaliplatin single agent has been evaluated in paediatric population in 2 Phase I (69</p><p>patients) and 2 Phase II (166 patients) studies. A total of 235 paediatric patients (7</p><p>months-22 years of age) with solid tumours have been treated. The effectiveness of</p><p>oxaliplatin single agent in the paediatric populations treated has not been established.</p><p>Accrual in both Phase II studies was stopped for lack of tumour response</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>The pharmacokinetics of individual active compounds have not been determined. The pharmacokinetics of ultrafiltrable platinum, representing a mixture of all unbound, active and inactive platinum species, following a two-hour infusion of oxaliplatin at 130 mg /m&sup2; every three weeks for 1 to 5 cycles and oxaliplatin at 85 mg/m&sup2; every two weeks for 1 to 3 cycles are as follows:</p><p>&nbsp;</p><p>Summary of Platinum Pharmacokinetic Parameter Estimates in Ultrafiltrate Following Multiple Doses of Oxaliplatin at 85 mg/m<sup>2</sup> Every Two Weeks or at 130 mg/m<sup>2</sup> Every Three Weeks</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>AUC0-48</p></td><td style="vertical-align:top"><p>AUC</p></td><td style="vertical-align:top"><p>t<sub>1/2&alpha;</sub></p></td><td style="vertical-align:top"><p>t <sub>1/2&beta;</sub></p></td><td style="vertical-align:top"><p>t<sub>1/2&gamma;</sub></p></td><td style="vertical-align:top"><p>Vss</p></td><td style="vertical-align:top"><p>CL</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&mu; g/ml</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&mu;g.h/ml</p></td><td style="vertical-align:top"><p>&nbsp;&mu;g.h/ml</p></td><td style="vertical-align:top"><p>h</p></td><td style="vertical-align:top"><p>h</p></td><td style="vertical-align:top"><p>h</p></td><td style="vertical-align:top"><p>L</p></td><td style="vertical-align:top"><p>L/h</p></td></tr><tr><td style="vertical-align:top"><p>85 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>0.814</p></td><td style="vertical-align:top"><p>4.19</p></td><td style="vertical-align:top"><p>4.68</p></td><td style="vertical-align:top"><p>0.43</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>391</p></td><td style="vertical-align:top"><p>440</p></td><td style="vertical-align:top"><p>17.4</p></td></tr><tr><td style="vertical-align:top"><p>SD</p></td><td style="vertical-align:top"><p>0.193</p></td><td style="vertical-align:top"><p>0.647</p></td><td style="vertical-align:top"><p>1.40</p></td><td style="vertical-align:top"><p>0.35</p></td><td style="vertical-align:top"><p>5.74</p></td><td style="vertical-align:top"><p>406</p></td><td style="vertical-align:top"><p>199</p></td><td style="vertical-align:top"><p>6.35</p></td></tr><tr><td style="vertical-align:top"><p>130 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>1.21</p></td><td style="vertical-align:top"><p>8.20</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>0.28</p></td><td style="vertical-align:top"><p>16.3</p></td><td style="vertical-align:top"><p>273</p></td><td style="vertical-align:top"><p>582</p></td><td style="vertical-align:top"><p>10.1</p></td></tr><tr><td style="vertical-align:top"><p>SD</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>2.40</p></td><td style="vertical-align:top"><p>4.60</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>2.90</p></td><td style="vertical-align:top"><p>19.0</p></td><td style="vertical-align:top"><p>261</p></td><td style="vertical-align:top"><p>3.07</p></td></tr></tbody></table><p>Mean AUC<sub>0-48</sub>, and C<sub>max</sub> values were determined on Cycle 3 (85 mg/m<sup>2</sup>) or cycle 5 (130 mg/m<sup>2</sup>).</p><p>Mean AUC, Vss and CL<sub> </sub>values were determined on Cycle 1.</p><p>C<sub>max</sub>, AUC, AUC<sub>0-48</sub>, Vss and CL values were determined by non-compartmental analysis.</p><p>t<sub>1/2&alpha;</sub>, t <sub>1/2&beta;</sub>, and t<sub>1/2&gamma;</sub>, were determined by compartmental analysis (Cycles 1-3 combined).</p><p>&nbsp;</p><p>Distribution</p><p>At the end of a 2-hour infusion, 15% of the administered platinum is present in the systemic circulation, the remaining 85% being rapidly distributed into tissues or eliminated in the urine. Irreversible binding to red blood cells and plasma, results in half-lives in these matrices that are close to the natural turnover of red blood cells and serum albumin. No accumulation was observed in plasma ultrafiltrate following 85 mg/m<sup>2</sup> every two weeks or 130mg/m<sup>2 </sup>every three weeks and steady state was attained by cycle one in this matrix. Inter- and intra-subject variability is generally low.</p><p>&nbsp;</p><p>Biotransformation</p><p>Biotransformation in vitro is considered to be the result of non-enzymatic degradation and there is no evidence of cytochrome P450-mediated metabolism of the diaminocyclohexane (DACH) ring.</p><p>&nbsp;</p><p>Oxaliplatin undergoes extensive biotransformation in patients, and no intact active substance was detectable in plasma ultrafiltrate at the end of a 2h-infusion. Several cytotoxic biotransformation products including the monochloro-, dichloro- and diaquo-DACH platinum species have been identified in the systemic circulation together with a number of inactive conjugates at later time points.</p><p>&nbsp;</p><p>Elimination</p><p>Platinum is predominantly excreted in urine, with clearance mainly in the 48 hours following administration.</p><p>&nbsp;</p><p>By day 5, approximately 54% of the total dose was recovered in the urine and &lt; 3% in the faeces.</p><p>&nbsp;</p><p>The effect of renal impairment on the disposition of oxaliplatin was studied in patients with varying degrees of renal function.</p><p>&nbsp;</p><p>Oxaliplatin was administered at a dose of 85 mg/m2 in the control group with a normal renal function (CLcr &gt; 80 ml/min, n=12) and in patients with mild (CLcr = 50 to 80 ml/min, n=13) and moderate (CLcr = 30 to 49 ml/min, n=11) renal impairment, and at a dose of 65 mg/m2 in patients with severe renal impairment (CLcr &lt; 30 ml/min, n=5). Median exposure was 9, 4, 6, and 3 cycles, respectively, and PK data at cycle 1 were obtained in 11, 13, 10, and 4 patients respectively.</p><p>&nbsp;</p><p>There was an increase in plasma ultrafiltrate (PUF) platinum AUC, AUC/dose and a decrease in total and renal CL and Vss with increasing renal impairment especially in the (small) group of patients with severe renal impairment: point estimate (90% CI) of estimated mean ratios by renal status versus normal renal function for AUC/dose were 1.36 (1.08, 1.71), 2.34 (1.82, 3.01) and 4.81 (3.49, 6.64) for patients with mild and&nbsp; moderate and in severe renal failure respectively.</p><p>&nbsp;</p><p>Elimination of oxaliplatin is significantly correlated with the creatinine clearance.</p><p>Total PUF platinum CL was respectively 0.74 (0.59, 0.92), 0.43 (0.33, 0.55) and 0.21 (0.15, 0.29) and for Vss respectively 0.52 (0.41, 0.65), 0.73 (0.59, 0.91) and 0.27 (0.20, 0.36) for patients with mild, moderate and severe renal failure respectively. Total body clearance of PUF platinum was therefore reduced by respectively 26% in mild, 57% in moderate, and 79% in severe renal impairment compared to patients with normal function.</p><p>&nbsp;</p><p>Renal clearance of PUF platinum was reduced in patients with impaired renal function by 30% in mild, 65% in moderate, and 84% in severe renal impairment compared to</p><p>patients with normal function.</p><p>&nbsp;</p><p>There was an increase in beta half life of PUF platinum with increasing degree of renal impairment mainly in the severe group.</p><p>&nbsp;</p><p>Despite the small number of patients with severe renal dysfunction, these data are of concern in patients in severe renal failure and should be taken into account when prescribing oxaliplatin in patients with renal impairment (see sections 4.2, 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The target organs identified in preclinical species (mice, rats, dogs, and/or monkeys) in single- and multiple-dose studies included the bone marrow, the gastrointestinal system, the kidney, the testes, the nervous system, and the heart. The target organ toxicities observed in animals are consistent with those produced by other platinum-containing medicinal products and DNA-damaging, cytotoxic medicinal products used in the treatment of human cancers with the exception of the effects produced on the heart. Effects on the heart were observed only in the dog and included electrophysiological disturbances with lethal ventricular fibrillation. Cardiotoxicity is considered specific to the dog not only because it was observed in the dog alone but also because doses similar to those producing lethal cardiotoxicity in dogs (150 mg/m<sup>2</sup>) were well-tolerated by humans. Preclinical studies using rat sensory neurons suggest that the acute neurosensory symptoms related to Oxaliplatin may involve an interaction with voltage-gated Na+ channels.</p><p>&nbsp;</p><p>Oxaliplatin was mutagenic and clastogenic in mammalian test systems and produced embryo‑fetal toxicity in rats. Oxaliplatin is considered a probable carcinogen, although carcinogenic studies have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for Injections</p><p>Tartaric acid</p><p>Sodium Hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be mixed with other medicinal products except for those mentioned in section 6.6. &nbsp;Oxaliplatin can be co-administered with folinic acid via a Y-line.</p><p>&nbsp;</p><p>- DO NOT mix with alkaline medicinal products or solutions, in particular 5-fluorouracil, folinic acid preparations containing trometamol as an excipients and trometamol salts of other medicinal products. &nbsp;Alkaline drugs or solutions will adversely affect the stability of oxaliplatin (see section 6.6).</p><p>- DO NOT dilute oxaliplatin with saline or other solutions containing chloride ions (including calcium, potassium or sodium chlorides).</p><p>- DO NOT use injection equipment containing aluminium.</p><p>- DO NOT mix with other medicinal products in the same infusion bag or line (see section 6.6 to check instructions related to co-administration with folinic acid)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use this medicine after the expiry date which is stated on the carton and label. The expiry date refers to the last day of that month. 

Shelf life: 18 months.

Inspect visually prior to use. Only clear solutions without particles should be used.

After dilution in 5% glucose, chemical and physical in-use stability has been demonstrated for 24 hours at +2°C - +8°C and for 6 hours at +25°C.

From a microbiological point of view, the solution for infusion should be used immediately. 

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C unless dilution has taken place in controlled and validated aseptic conditions.
  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p><p>&nbsp;</p><p>Medicinal product as packaged for sale: Keep the vial in the outer carton in order to protect from light. &nbsp;Do not freeze.</p><p>&nbsp;</p><p>For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 vial with 10 ml concentrate (Type I clear glass vial with or without Onco-Tain sleeve) with elastomeric stopper and flip-off cap.</p><p>&nbsp;</p><p>1 vial with 20 ml concentrate (Type I clear glass vial with or without Onco-Tain sleeve) with elastomeric stopper and flip-off cap.</p><p>&nbsp;</p><p>1 vial with 40 ml concentrate (Type I clear glass vial with or without Onco-Tain sleeve) with elastomeric stopper and flip-off cap.</p><p>&nbsp;</p><p>Pack size: 1 vial per box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other potentially toxic compounds, caution should be exercised when handling and preparing oxaliplatin solutions.</p><p>&nbsp;</p><p>Instructions for Handling</p><p>&nbsp;</p><p>The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee the protection of the handler and his surroundings.</p><p>&nbsp;</p><p>The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the medicinal<strong><em> </em></strong>product, the protection of the environment and in particular the protection of the personnel handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.</p><p>&nbsp;</p><p>Personnel must be provided with appropriate handling materials, notably long sleeved gowns, protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste.</p><p>&nbsp;</p><p>Excreta and vomit must be handled with care.</p><p>&nbsp;</p><p>Pregnant women must be warned to avoid handling cytotoxic agents.</p><p>&nbsp;</p><p>Any broken container must be treated with the same precautions and considered as contaminated waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below chapter &ldquo;Disposal&rdquo;.</p><p>&nbsp;</p><p>If oxaliplatin concentrate or solution for infusion, should come into contact with skin, wash immediately and thoroughly with water.</p><p>&nbsp;</p><p>If oxaliplatin concentrate or solution for infusion, should come into contact with mucous membranes, wash immediately and thoroughly with water.</p><p>&nbsp;</p><p>Special precautions for administration</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT use injection material containing aluminium.</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT administer undiluted.</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only glucose 5% infusion solution is to be used as a diluent. &nbsp;DO NOT dilute for infusion with sodium chloride or chloride containing solutions.</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT mix with any other medicinal products in the same infusion bag or administer simultaneously by the same infusion line.</p><p>&nbsp;</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT mix with alkaline drugs or solutions, in particular 5-fluorouracil, folinic acid preparations containing trometamol as an excipients and trometamol salts of other drugs. &nbsp;Alkaline drugs or solutions will adversely affect the stability of oxaliplatin.</p><p>&nbsp;</p><p><em><u>Instruction for use with folinic acid (as calcium folinate or disodium folinate)</u></em><br />&nbsp;</p><p>Oxaliplatin 85&nbsp;mg/m&sup2; intravenous infusion in 250 to 500&nbsp;ml of glucose 5&nbsp;% solution is given at the same time as folinic acid intravenous infusion in glucose 5&nbsp;% solution, over 2 to 6&nbsp;hours, using a Y-line placed immediately before the site of infusion.</p><p>&nbsp;</p><p>These two medicinal products should <strong>not </strong>be combined in the same infusion bag. Folinic acid must not contain trometamol as an excipient and must only be diluted using isotonic glucose 5&nbsp;% solution, never in alkaline solutions or sodium chloride or chloride containing solutions.</p><p><u>&nbsp;</u></p><p><em><u>Instruction for use with 5-fluorouracil (5FU)</u></em></p><p>&nbsp;</p><p>Oxaliplatin should always be administered before fluoropyrimidines &ndash; i.e. 5-fluorouracil (5-FU). After oxaliplatin administration, flush the line and then administer 5-fluorouracil (5-FU).</p><p>&nbsp;</p><p>For additional information on drugs combined with oxaliplatin, see the corresponding manufacturer&rsquo;s summary of product characteristics.</p><p>&nbsp;</p><p><em>Concentrate for solution for infusion</em></p><p><u>&nbsp;</u></p><p>Inspect visually prior to use. Only clear solutions without particles should be used. The medicinal product is for single use only. Any unused concentrate should be discarded.</p><p>&nbsp;</p><p><em><u>Dilution for intravenous infusion </u></em></p><p>&nbsp;</p><p>Withdraw the required amount of concentrate from the vial(s) and then dilute with 250 ml to 500 ml of a glucose 5% solution to give an oxaliplatin concentration between 0.2 mg/ml and 0.7&nbsp;mg/ml. The concentration range over which the physico-chemical stability of oxaliplatin has been demonstrated is 0.2 mg/ml to 1.3 mg/ml.</p><p>&nbsp;</p><p>Administer by intravenous infusion.</p><p>&nbsp;</p><p>After dilution in 5% glucose, chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C and for 6 hours at 25&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, this infusion preparation should be used immediately.</p><p>&nbsp;</p><p>If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2&deg;C to 8&deg;C unless dilution has taken place in controlled and validated aseptic conditions.</p><p>&nbsp;</p><p>Inspect visually prior to use. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>The medicinal product is for single use only. Any unused infusion solution should be discarded.</p><p>&nbsp;</p><p><strong>NEVER </strong>use sodium chloride or chloride containing solutions for dilution.</p><p>&nbsp;</p><p>The compatibility of Oxaliplatin solution for infusion has been tested with representative, PVC-based, administration sets.</p><p>&nbsp;</p><p>Infusion</p><p>&nbsp;</p><p>The administration of oxaliplatin does not require prehydration.</p><p>&nbsp;</p><p>Oxaliplatin diluted in 250 to 500 ml of a glucose 5% solution to give a concentration not less than 0.2 mg/ml <strong>must</strong> be infused either by peripheral vein or central venous line over 2 to 6&nbsp;hours. When oxaliplatin is administered with 5-fluorouracil (5-FU), the oxaliplatin infusion must precede the administration of 5-fluorouracil (5-FU).</p><p>&nbsp;</p><p><u>Disposal </u></p><p>&nbsp;</p><p>Remnants of the medicinal product as well as all materials that have been used for dilution and administration must be destroyed according to hospital standard procedures applicable to cytotoxic agents and in accordance with local requirements related to the disposal of hazardous waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER  
Hospira UK Ltd
Horizon
Honey Lane
Hurley
Maidenhead
SL6 6RJ
UK

Manufacturer:
 
Zydus Hospira Oncology Private Limited, Plot No.3, Pharmez - Special Economic Zone, Sarkhej Bavla Highway, (N.H, No. 8A), Matoda, Taluka Sanand, District Ahmedabad – 382213, Ahmedabad, India


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>